

Executive Summary

Orio Therapeutics is a regenerative medicine start-up based on a patented drug-delivery technology developed by its co-founders at Monash University, Australia. The co-founders have negotiated an exclusive license with Monash University that will be triggered upon securing seed funding.

More specifically, the co-founders of Orio Therapeutics have developed a drug-delivery technology based on protein engineering. This modifies therapeutic proteins, allowing for greater therapeutic effects with lower doses by ensuring they remain at the injection site. This technology has the potential to transform the field of regenerative medicine and revolutionize the way we approach tissue regeneration and repair, while addressing unmet medical needs and improving patient outcomes. We demonstrated the efficacy of this platform in animal models of skin, bone, skeletal muscle, and cardiac muscle regeneration or preservation. The technology can be applied to virtually any protein therapeutic requiring a local action and we will initially focus our efforts on an application in acute myocardial infarct patients.

Acting on the inflammatory response that follows a heart attack, our first product prevents the death of cardiac muscle cells. This technology has the potential to save the life of countless victims of heart attacks while improving the quality of life and recovery prognosis of others. Our approach has demonstrated promising results in mouse models, and we are currently moving towards pre-clinical studies on porcine models.

Orio Therapeutics is hosted on the site of BioArk, in Monthey, and benefits from the support of The Ark foundation, based and financed in the canton of Valais, Switzerland. The Ark provides coaching, access to a vast network of potential investors and partners, lab space, and non-dilutive funding on a project basis. Moreover, Switzerland has one of the densest networks of biotech companies in the world, which is one of the driving forces of its thriving economy. Very tight networks have been created between the industry and public hospitals and universities. This greatly promotes technology transfer and collaboration between academia and industry and often facilitates the transition to clinical trials and presents a wide array of potential collaborations for Orio Therapeutics.

The company has the opportunity to pursue two business models: develop our first product until completion of phase I and aim at an exit through acquisition at this stage, or leverage the versatility of our core technology to develop a pipeline of products in the field of regenerative medicine. In the later scenario Orio Therapeutics would out-license the rights of its first product and take on co-development contracts to improve existing protein therapeutics of larger companies while developing in-house products.

To progress in its development, Orio Therapeutics is now seeking seed capital to expand the team and undertake pre-clinical studies.